doi: 10.1016/j.redox.2023.102604, 73 KalsbeekM
Research Use Only: All products sold through this website are supplied exclusively for laboratory and scientific research
Anti-estrogen-based endocrine therapies, such as the ER modulator Tamoxifen, ER degrader Fulvestrant, and the aromatase inhibitor Letrozole, have significantly enhanced the survival rates of patients with hormone receptor-positive (HR+) breast cancer [5]
Roh et al 88 investigated the therapeutic effects of a genistein derivative, in a 1% topical formulation, on SCC caused by chronic solar-simulated light (SSL)
Anthracycline radical formation by NADH dehydrogenase
However, analysis of 20% weight loss was not performed for the 0.3 mg and placebo groups because no participants in those arms achieved that degree of reduction [1]